Scarica l'app Stockscreener
4.3997
0.69%
0.0397
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.36
Aprire:
$4.35
Volume 24 ore:
9.28M
Relative Volume:
0.22
Capitalizzazione di mercato:
$2.29B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-2.8385
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
-6.20%
1M Prestazione:
+1.39%
6M Prestazione:
-15.90%
1 anno Prestazione:
-39.36%
Intervallo 1D:
$4.30
$4.43
Intervallo di 1 settimana:
$4.18
$4.96
Portata 52W:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.40 | 2.27B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.60 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.41 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition - ts2.tech
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? - Barchart.com
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation - Yahoo Finance
Is Recursion Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Market Mood & High Accuracy Trade Alerts - Bölüm Sonu Canavarı
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Yahoo! Finance Canada
Aug Retail: Will Recursion Pharmaceuticals Inc stock gain from lower inflationMarket Volume Summary & Daily Profit Maximizing Trade Tips - moha.gov.vn
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Insider Monkey
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025 - ts2.tech
Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
Is Recursion Pharmaceuticals Inc. stock a safe buy before earningsJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - Улправда
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next - ts2.tech
Published on: 2025-12-19 22:42:25 - Улправда
CEO Gibson Files To Sell 40,000 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView — Track All Markets
Will Recursion Pharmaceuticals Inc. stock benefit from green energy trends2025 Trading Recap & AI Based Trade Execution Alerts - DonanımHaber
Cathie Wood’s ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals - Investing.com
Can Recursion Pharmaceuticals Inc. stock surprise with earnings upsidePortfolio Profit Report & Daily Chart Pattern Signals - DonanımHaber
Is Recursion Pharmaceuticals a Meme Stock? - MSN
How Recursion Pharmaceuticals Inc. stock compares to growth peersTrade Performance Summary & Weekly Market Pulse Updates - DonanımHaber
How Recursion Pharmaceuticals Inc. stock compares to market leadersPortfolio Risk Summary & Low Risk Investment Opportunities - DonanımHaber
What hedge fund activity signals for Recursion Pharmaceuticals Inc. stock2025 Sector Review & Smart Swing Trading Alerts - Улправда
Why Recursion Pharmaceuticals, Inc. (RXRX)'s upside case hasn't fully convinced yet - MSN
RXRX Stock: Analyzing the Dive and Its Impact - StocksToTrade
RXRX Stock Insight: Unraveling Latest Developments - timothysykes.com
Update Report: Is Recursion Pharmaceuticals Inc stock overvalued by current metricsCEO Change & Precise Buy Zone Tips - moha.gov.vn
Recursion Pharmaceuticals: Upgrading To BuyMy Most Surprising Call Of 2025 (RXRX) - Seeking Alpha
RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains - Forbes
Is Recursion Pharmaceuticals Stock Attractive? - Trefis
Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet - Finviz
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next - ts2.tech
Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet - Insider Monkey
What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders - simplywall.st
U.S. stock market movement | AI healthcare concept stock Recursion continues to rise 3.8% in pre-market trading, Morgan Stanley raises rating + Cathie Wood increases position. - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX) - The Globe and Mail
JPMorgan has upgraded Recursion (RXRX.US) to an 'Overweight' rating, with its core pipeline candidate REC-4881 expected to become a blockbuster drug. - 富途牛牛
Backed by Nvidia, Recursion Soars 11% Following Bullish Analyst Call and Clinical Trial Update - NAI500
Why Recursion Pharmaceuticals stock vaulted 11% higher on Wednesday - MSN
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday - AOL.com
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - Nasdaq
CFO Taylor Surrenders 7,057 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView — Track All Markets
Stock Traders Buy Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks making the biggest moves today - MSN
Recursion Pharmaceuticals: Is Now the Time to Invest? - StocksToTrade
Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade - marketscreener.com
Top Biotech Stocks To ResearchDecember 17th - MarketBeat
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why - Benzinga
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today - Stocktwits
10 Best NASDAQ Stocks Under $10 to Buy - Insider Monkey
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Recursion Pharmaceuticals Inc Azioni (RXRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
Dec 19 '25 |
Sale |
4.50 |
40,000 |
180,000 |
913,839 |
0.36%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):